Navigation Links
Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Date:4/24/2008

PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company and participate in a discussion moderated by Morgan Stanley representatives on Wednesday, April 30, 2008 at 3:40 PM (ET) in the Plaza Ballroom.

To access a simultaneous webcast of Mr. Price's overview and discussion via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation, if any, will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
2. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
3. Pharmasset Receives $10 Million of Working Capital
4. Pharmasset Appoints Herbert J. Conrad as a Director
5. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
6. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Pharmasset Appoints Michael Rogers as Chief Development Officer
10. Pharmasset to Present at Three Investor Conferences in November 2007
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. (PRWEB) August 21, 2014 The ... the first private college in the Mid-Hudson Region to ... will now begin accepting applications from qualified “high-technology” businesses ... “We are very pleased to have been selected for ... Governor Cuomo’s transformative initiative to stimulate economic development in ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced today ... 2007 highlights, Major pipeline progress:, - ... cSSSI,achieves its pre-specified primary endpoint, as did the first, ... intravenous iclaprim in,cSSSI initiated, - First patients enrolled ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the management of ... SURGICAL IMPLANT is a biodegradable and fully,bioresorbable ...
... 13 Kansas has long,been known for its ... many have not realized, however, is that Kansas, ... far beyond the farm,-- namely, the scientific laboratory., ... and the,animal-health industry have positioned the state squarely ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... rainforests are often called the "lungs of the planet" because ... But the amount of carbon dioxide that rainforests absorb, or ... a paper published online this week (Feb 6 2013) by ... from the University of Exeter, the Met Office-Hadley Centre and ...
... A closer look at personalized or point-of-care healthcare ... in India organized and chaired by NJIT Distinguished ... Medicine and Biology Society (EMBS) International Special Topic ... the world, focused on topics ranging from 21st ...
... Virginia Commonwealth University Massey Cancer Center suggest that a ... potentially be an effective new therapy for several forms ... and mantle cell lymphoma (MCL). The study, ... showed that the experimental drug combination killed cancer cells ...
Cached Biology News:Lungs of the planet reveal their true sensitivity to global warming 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 3Experimental drug combination selectively destroys lymphoma cells 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... to a lesser extent in breast, lung ... Ab-2 shows no cross-reaction with MUC1 and ... the human MUC3 Immunogen: MUC3 ...
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: